case_images: PMC6198101_01
case_images: Image of the clinical course in case 1, a luminal-HER2 type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when recurrence detected, and (**) radiologically complete remission. Ope = operation; RTx = radiotherapy; CTx = chemotherapy; ETx = endocrine therapy; cCR = clinical complete response; MBC = metastatic breast cancer.
case_images: gr1.jpg
case_images: PMC6198101_01_gr1.jpg
case_images: fig0005
case_images: The last follow up was August 2018 and she has survived for 11.5 year after termination of anti-HER2 therapy (Fig. 1).
case_images: PMC6198101_02
case_images: Image of the clinical course in case 2, a HER2-enriched type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when recurrence detected, and (**) radiologically complete remission. Scar remained in her right lung because the patient received video assisted thoracic surgery as biopsy from metastatic site.. Op = operation; RTx = radiotherapy; CTx = chemotherapy; cCR = clinical complete response; MBC = metastatic breast cancer
case_images: gr2.jpg
case_images: PMC6198101_02_gr2.jpg
case_images: fig0010
case_images: The last follow up was August, 2018 and she has survived for 10 months after termination of anti-HER2 therapy (Fig. 2).
case_images: PMC6198101_03
case_images: Image of the clinical course in case 3, a HER2-enriched type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when the patient was diagnosed with MBC, and (**) radiologically complete remission. The patient did not receive surgical recession of tumor region. Op = operation; RTx = radiotherapy; CTx = chemotherapy; cCR = clinical complete response; MBC = metastatic breast cancer.
case_images: gr3.jpg
case_images: PMC6198101_03_gr3.jpg
case_images: fig0015
case_images: The last follow up was June 2018 and she has survived for 2 years and a half month after termination of anti-HER2 therapy (Fig. 3).
case_images: PMC6198101_04
case_images: Image of the clinical course in case 4, a HER2-enriched type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when the patient was diagnosed with MBC, and (**) radiologically complete remission. The patient received mastectomy and sentinel lymph node biopsy, proving pathological complete response in the left breast. (C) Tapering trastuzumab for termination after maintenance therapy. The dose of trastuzumab was gradually reduced in all patients.. Op = operation; RTx = radiotherapy; CTx = chemotherapy; cCR = clinical complete response; MBC = metastatic breast cancer
case_images: gr4.jpg
case_images: PMC6198101_04_gr4.jpg
case_images: fig0020
case_images: The last follow up was July, 2018 and she has survived for 8 months after termination of anti-HER2 therapy (Fig. 4).